Efficacy and Survival Analysis of Chidamide Combined with DICE Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.02.010
- Author:
Li-Li WU
1
;
Li SHI
1
;
Wei-Jing LI
1
;
Wei LIU
1
;
Yun FENG
1
;
Shao-Ning YIN
1
;
Cui-Ying HE
1
;
Li-Hong LIU
1
Author Information
1. Department of Hematology， The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
- Publication Type:Journal Article
- Keywords:
relapsed/refractory;
diffuse large B-cell lymphoma;
double-expression;
chidamide;
curative effect;
adverse event
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Middle Aged;
Female;
Male;
Adult;
Aged;
Retrospective Studies;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Benzamides/administration & dosage*;
Aminopyridines/administration & dosage*;
Etoposide/therapeutic use*;
Cisplatin/administration & dosage*;
Ifosfamide/administration & dosage*;
Dexamethasone/therapeutic use*
- From:
Journal of Experimental Hematology
2025;33(2):373-378
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of chidamide combined with DICE regimen (cisplatin+ ifosfamide + etoposide + dexamethasone) for relapsed/refractory diffuse large B-cell lymphome(R/R DLBCL).
METHODS:The clinical data of 31 R/R DLBCL patients treated by chidamide combined with DICE regimen in the Hematology Department of the Fourth Hospital of Hebei Medical University from October 2016 to October 2020 were retrospectively analyzed. The clinical efficacy and adverse events were observed.
RESULTS:Among the 31 patients, 20 were male and 11 were female. The median age of the patients was 55 (range: 27-71) years old, 21 cases were < 60 years old, 10 cases were ≥60 years old. 26 cases were refractory and 5 cases were relapsed. There were 13 cases of germinal center B-cell like (GCB), 17 cases of non-GCB, and 1 case had missing Hans type. There were 17 cases of double-expression lymphoma (DEL) and 14 cases of non-DEL. The complete response rate of patients was 38.7%(12/31), the overall response rate was 67.7%(21/31). The median progression-free survival time and the median overall survival time were 9.8(95%CI : 4.048-15.552) months, 13.9(95%CI : 9.294-18.506) months, respectively. Multipvariate analysis showed that GCB and DEL reduced the risk of disease recurrence in R/R DLBCL patients. The main grade 3/4 hematological adverse events in this study were thrombocytopenia, agranulocytosis, anemia and leukopenia.
CONCLUSION:The chidamide combined with DICE regimen is effective in the treatment of R/R DLBCL, and hematological adverse events should be closely monitored.
